Achilles Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHL research report →
About the company
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma.
- CEO
- Iraj Ali
- IPO
- 2021
- Employees
- 204
- HQ
- London, GB
Price Chart
- Market Cap
- $60.83M
- P/E
- -0.85
- P/S
- 0.00
- P/B
- 0.42
- EV/EBITDA
- 0.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.05%
- ROIC
- -50.85%
- Revenue
- $0 · 0.00%
- Net Income
- $-69,665,000 · 2.12%
- EPS
- $-1.74 · 4.40%
- Op Income
- $-75,255,000
- FCF YoY
- 26.10%
- 52W High
- $1.51
- 52W Low
- $0.63
- 50D MA
- $1.33
- 200D MA
- $1.03
- Beta
- 1.25
- Avg Volume
- 1.28M
Get TickerSpark's AI analysis on ACHL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ACHL coverage
Recent articles, reports, and earnings notes.
No research on ACHL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACHL report →Similar companies
Peers in the same neighborhood.